An international team of researchers have introduced a groundbreaking drug, known as the covalent kinase inhibitor, which shows promise in combating treatment-resistant malaria.Developed by chemists ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Hundreds of millions of dollars of life-saving medical supplies are stranded in warehouses and on ships around the world due ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Now that he has been confirmed as Secretary of Health and Human Services, Kennedy must recognize that his performance is a ...

New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and patient-important outcomes.

Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...